ARTICLE | Company News
Oncothyreon, Braeburn deal
July 13, 2015 7:00 AM UTC
Oncothyreon granted Braeburn rights to develop and commercialize ATI-9242, a next-generation atypical antipsychotic agent modeled on clozapine that has completed a Phase I trial to treat schizophrenia...